David Nierengarten
Stock Analyst at Wedbush
(4.00)
# 590
Out of 5,008 analysts
200
Total ratings
49.69%
Success rate
11.91%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVB Nuvation Bio | Reiterates: Outperform | $6 | $3.66 | +63.93% | 10 | Sep 8, 2025 | |
| NUVL Nuvalent | Reiterates: Outperform | $115 | $83.38 | +37.92% | 6 | Sep 8, 2025 | |
| STTK Shattuck Labs | Initiates: Outperform | $4 | $2.45 | +63.27% | 1 | Sep 8, 2025 | |
| XNCR Xencor | Reiterates: Outperform | $26 | $12.03 | +116.13% | 8 | Sep 2, 2025 | |
| TLX Telix Pharmaceuticals | Reiterates: Outperform | $22 | $9.99 | +120.22% | 3 | Aug 28, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $12.34 | +102.59% | 1 | Aug 18, 2025 | |
| GBIO Generation Bio Co. | Downgrades: Neutral | $7 | $6.23 | +12.36% | 9 | Aug 13, 2025 | |
| VOR Vor Biopharma | Reiterates: Neutral | $8 | $33.80 | -76.33% | 8 | Jun 26, 2025 | |
| ARGX argenx SE | Reiterates: Outperform | $715 | $797.35 | -10.33% | 21 | Jun 24, 2025 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $3.47 | +217.00% | 4 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $20.44 | -51.08% | 10 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $27 | $14.16 | +90.68% | 8 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $34 | $38.12 | -10.81% | 3 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $13.82 | +138.78% | 6 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $0.84 | +137.45% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.39 | +259.71% | 15 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $18.17 | +70.61% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $29.87 | +33.91% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $39.73 | +126.53% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $39.50 | +18.99% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $14.12 | +41.64% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $20.56 | +94.55% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $16.02 | +180.90% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.97 | +407.61% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $2.90 | +520.69% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $67.89 | -16.04% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $15.44 | -35.23% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $5.87 | +104.43% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $25.13 | +126.82% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $50 → $175 | $7.96 | +2,098.49% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $3.49 | +14,226.65% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $5.77 | +939.86% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $9.47 | +100.63% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $29.74 | +152.19% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.23 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.73 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.17 | - | 3 | Nov 20, 2017 |
Nuvation Bio
Sep 8, 2025
Reiterates: Outperform
Price Target: $6
Current: $3.66
Upside: +63.93%
Nuvalent
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $83.38
Upside: +37.92%
Shattuck Labs
Sep 8, 2025
Initiates: Outperform
Price Target: $4
Current: $2.45
Upside: +63.27%
Xencor
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $12.03
Upside: +116.13%
Telix Pharmaceuticals
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $9.99
Upside: +120.22%
BridgeBio Oncology Therapeutics
Aug 18, 2025
Initiates: Outperform
Price Target: $25
Current: $12.34
Upside: +102.59%
Generation Bio Co.
Aug 13, 2025
Downgrades: Neutral
Price Target: $7
Current: $6.23
Upside: +12.36%
Vor Biopharma
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $33.80
Upside: -76.33%
argenx SE
Jun 24, 2025
Reiterates: Outperform
Price Target: $715
Current: $797.35
Upside: -10.33%
Perspective Therapeutics
Jun 23, 2025
Reiterates: Outperform
Price Target: $11
Current: $3.47
Upside: +217.00%
May 19, 2025
Reiterates: Neutral
Price Target: $10
Current: $20.44
Upside: -51.08%
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $14.16
Upside: +90.68%
Apr 16, 2025
Reiterates: Outperform
Price Target: $34
Current: $38.12
Upside: -10.81%
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $13.82
Upside: +138.78%
Mar 14, 2025
Downgrades: Neutral
Price Target: $8 → $2
Current: $0.84
Upside: +137.45%
Mar 6, 2025
Reiterates: Neutral
Price Target: $5
Current: $1.39
Upside: +259.71%
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $18.17
Upside: +70.61%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $29.87
Upside: +33.91%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $39.73
Upside: +126.53%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $39.50
Upside: +18.99%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $14.12
Upside: +41.64%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $20.56
Upside: +94.55%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $16.02
Upside: +180.90%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.97
Upside: +407.61%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $2.90
Upside: +520.69%
Aug 9, 2024
Reiterates: Outperform
Price Target: $57
Current: $67.89
Upside: -16.04%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $15.44
Upside: -35.23%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $5.87
Upside: +104.43%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $25.13
Upside: +126.82%
Feb 29, 2024
Upgrades: Outperform
Price Target: $50 → $175
Current: $7.96
Upside: +2,098.49%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $3.49
Upside: +14,226.65%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $5.77
Upside: +939.86%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $9.47
Upside: +100.63%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $29.74
Upside: +152.19%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.23
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $4.73
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $10.17
Upside: -